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Background: Hypnotics are widely used by the elderly, and their impact on mortality remains controversial. The
inconsistent findings could be due to methodological limitations, notably the lack of control for underlying sleep
symptoms or illness associated with hypnotic use, for example, insomnia symptoms and excessive daytime
sleepiness, depression and anxiety. Our objective was to examine the association between the use of hypnotics and
mortality risk in a large cohort of community-dwelling elderly, taking into account a wide range of potential
competing risks including sociodemographic characteristics, lifestyle, and chronic disorders as well as underlying
psychiatric disorders and sleep complaints.
Methods: Analyses were carried out on 6,696 participants aged 65 years or older randomly recruited from three
French cities and free of dementia at baseline. Adjusted Cox proportional hazards models with delayed entry, and
age of the participants as the time scale, were used to determine the association between hypnotic use and
12-year survival.
Results: At baseline, 21.7% of the participants regularly used at least one hypnotic. During follow-up, 1,307 persons
died, 480 from cancer and 344 from cardiovascular disease. Analyses adjusted for study center, age and gender
showed a significantly greater risk of all-cause and cardiovascular-related mortality with hypnotics, particularly
benzodiazepines, and this increased with the number of hypnotics used. None of these associations were
significant in models adjusting for sociodemographic and lifestyle characteristics, chronic disorders including
cardiovascular pathologies, sleep and psychiatric disorders. Results remained unchanged when duration of past
hypnotic intake or persistent versus intermittent use during follow-up were taken into account.
Conclusions: When controlling for a large range of potential confounders, the risk of mortality was not significantly
associated with hypnotic use regardless of the type and duration. Underlying psychiatric disorders appear to be the
principal confounders of the observed association.
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Sleep changes with advancing age; however, the high
prevalence of insomnia in the older adult population is
often due to associated age-related medical and psycho-
social comorbidities and the frequent use of medications
that may impact sleep per se [1]. Insomnia symptoms in
older adults are frequently associated with daytime fa-
tigue, excessive daytime sleepiness (EDS), and hypnotics* Correspondence: ydauvilliers@yahoo.fr
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reproduction in any medium, provided the oruse [2-4]. Insomnia and EDS are also frequently comor-
bid with other pathologies, notably cardiovascular dis-
eases (CVD) [5,6] and psychiatric disorder, for example,
anxiety and depression [2,4,7].
Hypnotics are indicated for treating insomnia symp-
toms, including those associated with anxiety and depres-
sion, and may also be used together with antidepressant
treatment. The current use of hypnotics in the general
population is estimated to range between 3.5% and 11.7%,
doubling in elderly populations [8-11]. Hypnotics may
produce residual daytime sleepiness and impairment of
psychomotor, attention and memory performances thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dose and long half-life durations [12]. Moreover, the use
of hypnotics seems to be associated with excess risk of
accidents such as falls and car accidents [12] and may in-
crease mortality risk, especially in elderly people with in-
creased pharmacodynamic alterations.
However, the high rate of insomnia, EDS complaints,
and psychiatric disorder in the elderly, their frequent co-
morbidity, and the potential risk of mortality associated
with both sleep disorders [13] and psychiatric disorders
[14,15] may override hypnotics as the cause of increased
mortality, independently of the underlying burden of
illness.
Overall, evidence suggesting an association between
hypnotics consumption and mortality in the elderly re-
mains controversial. Four observational studies in young
adults [16,17] and elderly people [18,19] found no sig-
nificant associations between hypnotics and all-cause
mortality. Other studies reported a significant associ-
ation with excessive all-cause deaths in adults [20-22].
Two large studies with very wide age ranges from young
adult to older elderly people [23-25] found significant as-
sociations in all age groups, including the elderly. Most of
the above studies controlled for sociodemographic charac-
teristics, lifestyle, and some chronic disorders but rarely or
not at all for the underlying medical conditions associated
with hypnotic prescription, that is depression, antidepres-
sant use, anxiety, insomnia, and EDS. Finally, no studies
examined the cumulative effect of hypnotics or the impact
of their long-term use on mortality risk in an elderly
population specifically. Several methodological issues may
contribute to the observed inconsistencies, including the
design of the study (retrospective or prospective); the
duration of follow-up (between 2.5 and 20 years); the het-
erogeneity in sample size and age range; the type and
duration of hypnotic prescription; and the lack of control
for psychiatric and sleep disorders (prescription/indication
biases).
The aim of the present study is to examine the associ-
ations between the use of hypnotics and 12-year mortal-
ity risk (all-causes, cancer and CVD) in a large cohort
of community-dwelling elderly people, taking into ac-
count a wide range of potential competing risks in-
cluding sociodemographic characteristics, lifestyle, and
chronic disorders as well as underlying psychiatric disor-
ders, EDS, and insomnia complaints. The impact of dur-
ation and type of hypnotic treatment were also evaluated.
Methods
Study population
Participants were recruited as part of the Three-City
Study, an ongoing multi-site longitudinal study involving
three French cities: Bordeaux, Dijon and Montpellier [26].
Briefly, non-institutionalized participants aged 65 years orover were randomly selected from electoral rolls between
1999 and 2001. The acceptance rate was 37%, yielding a
sample of 9,294 individuals.
The study protocol was approved by the ethical com-
mittee of the University Hospital of Kremlin-Bicêtre and
CPP Sud Méditérannée III, and written informed consent
was obtained from each participant. The participants were
administered standardized questionnaires and underwent
clinical examinations at baseline and after 2, 4, 8, 10 and
12 years.
Mortality
The exact date of death of the participants was obtained
from death registries. The causes of death were collected
by the local study centers from medical records and in-
terviews with family physicians, clinicians and other
non-medical informants (relatives or caregivers) [27]. A
validation committee used all information to classify the
cause of death using the tenth revision of International
Classification of Diseases (ICD-10) [28] as follows: can-
cer (ICD-10: C00 to C97 and D37 to D48), coronary
heart disease and stroke (ICD-10: I00 to I99 and R960 to
R961), respiratory (ICD-10: J00 to J99), and ill-defined
causes (ICD-10: R00 to R99).
Sociodemographic and clinical variables at baseline
The standardized interview included questions on demo-
graphic characteristics, level of education, living alone,
and on health behaviors (for example, consumption of
alcohol and smoking status). Information on the health of
the participants was obtained through detailed medical
questionnaires. Case-level depressive symptoms were de-
fined as a score above the 16-point cut-off on the Center
for Epidemiological Studies-Depression Scale [29]. Anx-
iety trait symptoms were measured using the Spielberger’s
State-Trait Anxiety Inventory [30]. In the absence of a val-
idated cut-off score in elderly populations, the state score
was divided into tertiles with the highest tertile (higher
level of anxiety) being compared to the two lowest tertiles.
Global cognitive function was assessed by the Mini-
Mental State Examination [31] and participants scoring
less than 26 were classified as cognitively impaired. Con-
finement was defined as social restriction (confinement to
bed, home or outings restricted to the neighborhood) [32].
Body mass index (BMI) was calculated as weight (kg)
divided by height squared (m2). The presence of hyper-
tension was defined by measured systolic blood pres-
sure ≥160 mmHg or diastolic blood pressure ≥95 mmHg
or current antihypertensive treatment. Diabetes was de-
fined as fasting glucose level ≥7.0 mmol/l or treatment for
diabetes. Hypercholesterolemia was defined as total chol-
esterol level ≥6.2 mmol/L or treatment with lipid-lowering
agents. Detailed medical questionnaires included past
history of respiratory and thyroid disorders, and cardio-
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infarction, cardiovascular surgery, arteritis, and stroke)
established according to standardized questions.
Sleep complaints at baseline
Sleep complaints were assessed at baseline as part of the
clinical interview, followed by the completion of a spe-
cific sleep questionnaire [33]. The participants self-rated
as ‘never, rarely, frequently, or often’ occurrence of being
excessively sleepy during the day (EDS), having difficul-
ties in initiating sleep (DIS), having several awakenings
during the night (difficulties in maintaining sleep; DMS),
having early morning awakening (EMA) without being
able to go back to sleep, and snoring loudly. In this ana-
lysis, EDS was defined as reporting frequently or often
being excessively sleepy. Insomnia complaints based on
DIS, DMS, and EMA were dichotomized as frequently/
often versus never/rarely and summed up to obtain a
number of insomnia complaints ranging from 0 to 3.
The risk of obstructive sleep apnea syndrome (OSAS) was
defined clinically as being obese (BMI ≥30 kg/m2), with
frequent/often EDS, and frequent/often loud snoring.
Medications and hypnotic use
At baseline and at 2, 4, and 8-year follow-up, an inven-
tory of all prescriptions and over-the-counter drugs used
during the preceding month was included in a standard-
ized interview. Medical prescriptions and the medica-
tions themselves were checked by the interviewer, thus
minimizing exposure misclassification. Current use of
antidepressants and hypnotics were coded according to
the World Health Organization’s Anatomical Therapeutic
Chemical Classification [34]. Hypnotics were classified as;
benzodiazepines (BZD), BZD-like compounds (zolpidem,
zopiclone), and miscellaneous medications (including bar-
biturates, antihistamines, and other pharmacological cat-
egories such as neuroleptics). At baseline, the participants
currently taking hypnotics were also requested to report
the duration of hypnotic intake.
Statistical analyses
Logistic regression models were used to compare the
characteristics of participants according to the use of
hypnotics at baseline after adjustment for study center,
age, and gender. To analyze the associations between
hypnotic use and risk of mortality, Cox proportional
hazard models with delayed entry and age of the partici-
pants as the time scale were used to estimate hazard ra-
tios (HR) and their 95% confidence intervals (CI). This
method gives better adjustment for age and is therefore
preferable for a sample of elderly individuals over the
standard model that uses study time as the time scale,
because the covariates are strongly associated with age
(for example, chronic diseases) [35,36]. Multivariate modelsincluded covariates that were associated with mortality at a
conservative level of P <0.15. Model 1 was adjusted for
study center, age, and gender. Model 2 was further adjusted
for education, alcohol intake, smoking status, BMI, confine-
ment, respiratory disorder, cognitive impairment, history of
CVD, hypertension, and diabetes. Two other models were
adjusted for diseases associated with hypnotic use to take
into account possible prescription bias, for example, num-
ber of insomnia complaints and EDS (model 3); and anx-
iety, depressive symptomatology, and antidepressant use
(model 4). The multivariate model 5 was adjusted for all
possible confounders. All-cause mortality was the principal
outcome defined for the analysis. In secondary analyses,
cause-specific mortality due to CVD and cancer was ana-
lyzed for separate end points. If both CVD and cancer were
reported as cause of death, both causes were considered in
the analysis. In all final models, significance level was set at
P <0.05. Analyses were performed using SAS statistical soft-
ware (version 9.2; SAS Inc, Cary, NC, USA).
Results
Study population
As shown in the study diagram (Figure 1), the study
sample included 6,696 participants free of dementia
(58.7% women) with a median age of 72.8 years (range,
65.0 to 95.0 years). The 2,382 participants free of dementia
excluded from the study were significantly more likely to be
older, have a lower education level, were more frequently
female and living alone, with confinement, hypertension,
diabetes, respiratory disease, hypercholesterolemia, de-
pressive and anxiety symptoms, cognitive impairment,
past history of cardio-cerebrovascular disease, and taking
more hypnotics (P <0.05 for all comparisons). They were
also more likely to have died during the follow-up period
(P <0.0001).
At baseline, 21.7% of the participants (n = 1,454) were
taking at least one hypnotic, 6.9% (n = 464) had three in-
somnia complaints, and 3.9% (n = 260) had no insomnia
complaints. More than 3% (n = 212) reported taking two
or more hypnotics. Regarding the main classes of hyp-
notics, 16% (n = 1070) took BZD, 4.8% (n = 321) BZD-
like compounds, and 3.0% (n = 204) miscellaneous med-
ications (of whom 54.4% took antihistamines, 25.0%
non-BZD anxiolytics, 18.6% barbiturates, and 4.4% neuro-
leptics). With regard to duration, 4.8% (n = 304) had been
taking hypnotics for less than 5 years, 3.9% (n = 244) be-
tween 5 and 10 years, 2.0% (n = 127) between 10 and 20
years, and 6.0% (n = 378) for more than 20 years.
Baseline sociodemographic and clinical characteristics
of the participants according to hypnotic use are de-
scribed in Table 1. An analysis adjusted for study center,
age, and gender showed that participants taking hyp-
notics had a lower education level; were more likely to
be confined to home; had more symptoms of depression,
Figure 1 Flow diagram. (1) For 41 participants, the cause of death was related to both cardiovascular and cancerb.
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had a past history of chronic disease (CVD, thyroid dis-
ease, diabetes, hypercholesterolemia); consumed less
caffeine; and reported more insomnia complaints and
EDS (P <0.05 for all comparisons).
Association between hypnotic use and 12-year mortality
The median follow-up time for the study was 8.9 years
with a range of 0.06 to 11.7 years. During this period,
1,307 (19.5%) deaths were observed. They were particu-
larly related to CVD (26.3%), cancer (36.8%), and co-
morbid CVD and cancer (3.1%). A substantial number
of deaths were due to ill-defined causes (21.6%) as the
result of multiple pathologies associated with frailty, and
10.2% died from respiratory diseases.
Baseline sociodemographic and clinical characteristics
in relation to follow-up mortality (all causes) are given
in Table 2. Participants who died during follow-up were
more frequently confined to home, obese, past or current
smoker, consuming less alcohol, had hypertension, dia-
betes mellitus, a past history of CVD, respiratory disease,
poorer cognitive performance, EDS, depressive symptoms,
or were taking antidepressants. They also tended to have alower level of education, and more frequently reported
insomnia and anxiety symptoms (P <0.15). Subsequent
analyses were adjusted for these factors. A significant
association was also found for participants at risk of
OSAS (n = 133; HR = 1.76; 95% CI = 1.31, 2.36; P =
0.0002).
Table 3 shows the associations between hypnotic use
at baseline and all-cause mortality over the 12-year
follow-up. After adjustment for age, gender, and study
center, the risk of all-cause mortality increased signifi-
cantly with the use of any hypnotic, the number of hyp-
notics, and alone for BZD (P <0.01 for all comparisons,
model 1). When potential lifestyle and chronic disorder
confounders were entered into the model (model 2), the
HR were reduced and failed to be significant except for
BZD (P = 0.05) and this was unchanged when further
adjusting for sleep complaints (model 3). When adjusting
for anxiety and depressive symptomatology (model 4), the
associations were not significant even for BZD (P = 0.22)
and this was also the case for the complete multivariate
model adjusted for all potential confounders (model 5).
BZD-like compounds, and miscellaneous medications in-
take were not associated with all-cause mortality even in
Table 1 Sociodemographic and clinical characteristics of participants according to hypnotic use at baseline
Hypnotic use
No N = 5,242 Yes N = 1,454
Variable n % n % Odds ratio [95% CI]a P
High level of educationb No 4,136 78.90 1,245 85.63 1 0.0006
Yes 1,106 21.10 209 14.37 0.75 [0.63;0.88]
Living alone Yes 1,610 30.71 605 41.61 1 0.06
No 3,632 69.29 849 58.39 0.88 [0.77;1.01]
Confinement No 5,025 95.86 1,314 90.37 1 <0.0001
Yes 217 4.14 140 9.63 1.90 [1.51;2.40]
Alcohol intake (g/day) <12 955 18.22 349 24.00 1 0.14
12 to 36 3,799 72.47 1,012 69.60 0.86 [0.75;1.00]
>36 488 9.31 93 6.40 0.92 [0.70;1.22]
Caffeine intake (mg/day) ≤125 1,310 24.99 423 29.09 1 0.007
125 to 375 3,103 59.19 836 57.50 0.83 [0.73;0.95]
>375 829 15.81 195 13.41 0.76 [0.62;0.92]
Smoking status Never 3,033 57.86 969 66.64 1 0.38
Past 1,901 36.26 402 27.65 0.99 [0.85;1.15]
Current 308 5.88 83 5.71 1.19 [0.92;1.55]
History of cardiovascular diseasec No 3,902 74.44 945 64.99 1 <0.0001
Yes 1,340 25.56 509 35.01 1.59 [1.40;1.81]
Respiratory disease No 4,945 94.33 1,364 93.81 1 0.35
Yes 297 5.67 90 6.19 1.13 [0.88;1.44]
Thyroid disease No 4,823 92.01 1,286 88.45 1 0.009
Yes 419 7.99 168 11.55 1.29 [1.07;1.57]
Depressive symptomatology No 4,295 81.93 897 61.69 1 <0.0001
Yes 947 18.07 557 38.31 2.76 [2.41;3.15]
Antidepressants intake No 5,081 96.93 1,196 82.26 1 <0.0001
Yes 161 3.07 258 17.74 6.32 [5.12;7.81]
Spielberger trait anxiety <43 3,688 70.35 715 49.17 1 <0.0001
≥43 1,554 29.65 739 50.83 2.33 [2.06;2.64]
Mini Mental State Examination Score ≥ 26 4,559 86.97 1,190 81.84 1 <0.0001
<26 683 13.03 264 18.16 1.40 [1.20;1.65]
Body mass index (kg/m2) Normal (<25) 2,477 47.25 747 51.38 1 0.41
Overweight (25 to 29) 2,106 40.18 515 35.42 0.92 [0.81;1.05]
Obese (≥30) 659 12.57 192 13.20 1.00 [0.83;1.20]
Hypertension No 2,175 41.49 538 37.00 1 0.08
Yes 3,067 58.51 916 63.00 1.12 [0.99;1.27]
Diabetes mellitus No 4,777 91.13 1,314 90.37 1 0.03
Yes 465 8.87 140 9.63 1.25 [1.02;1.54]
Hypercholesterolemia No 3,349 63.89 859 59.08 1 0.005
Yes 1,893 36.11 595 40.92 1.19 [1.05;1.34]
Snoring loudly (n = 5,972) Never/Rarely 3,021 64.30 863 67.74 1 0.63
Frequently/Often 1,677 35.70 411 32.26 0.97 [0.84;1.11]
Difficulties in initiating sleep Never/Rarely 3,760 71.73 641 44.09 1 <0.0001
Frequently/Often 1,482 28.27 813 55.91 2.85 [2.51;3.24]
Jaussent et al. BMC Medicine 2013, 11:212 Page 5 of 11
http://www.biomedcentral.com/1741-7015/11/212
Table 1 Sociodemographic and clinical characteristics of participants according to hypnotic use at baseline (Continued)
Difficulties in maintaining sleep Never/Rarely 2,029 38.71 455 31.29 1 <0.0001
Frequently/Often 3,213 61.29 999 68.71 1.29 [1.14;1.47]
Early morning awakening Never/Rarely 3,565 68.01 740 50.89 1 <0.0001
Frequently/Often 1,677 31.99 714 49.11 1.85 [1.64;2.09]
Number of insomnia complaintsd 0 1,586 30.26 260 17.88 1 <0.0001
1 1,729 32.98 326 22.42 1.15 [0.96;1.38]
2 1,138 21.71 404 27.79 2.02 [1.70;2.41]
3 789 15.05 464 31.91 3.07 [2.56;3.68]
Excessive daytime sleepiness Never/Rarely 4,384 83.63 1,165 80.12 1 0.005
Frequently/Often 858 16.37 289 19.88 1.25 [1.07;1.47]
aAdjustment for center study, age and gender; buniversity level; chistory of cardiovascular disease (stroke or coronary heart disease); dnumber of insomnia
complaints: difficulties in initiating sleep + difficulties in maintaining sleep + early morning awakening. CI, confidence interval.
Jaussent et al. BMC Medicine 2013, 11:212 Page 6 of 11
http://www.biomedcentral.com/1741-7015/11/212the minimally adjusted model 1. No significant interaction
was found for mortality between hypnotic use and EDS,
number of insomnia complaints, antidepressant use, chronic
diseases, or being at risk for OSAS.
The relationship between hypnotic intake and the risk
of mortality remained unchanged after exclusion of the
participants who died during the first two years of
follow-up (n = 134), the follow-up rate at two years be-
ing 88%. With regard to specific causes of death, the use
of hypnotics and BZD as well as number of hypnotics
were associated with a significantly increased risk of
CVD-related death in model 1, but not in the complete
multivariate model adjusted for all potential confounders
(Table 4). There was no significant association between
hypnotics and cancer-related death regardless of covari-
ates, even in the minimally-adjusted model 1 (P = 0.38).Duration of hypnotic use and mortality
Sensitivity analyses were performed to examine the rela-
tionship between persistent use of hypnotics during the
initial 4 years and all-cause mortality. A total of 3,496
participants (65.9%) did not report hypnotic use at base-
line or at follow-up examination, 773 (14.5%) reported
use both at baseline and at the first two follow-ups (per-
sistent users) and 1,040 (19.6%) were taking hypnotics at
one of two time points (intermittent users). The risk of
mortality for the next 8 years was not significantly asso-
ciated with the persistent use of hypnotics (when com-
pared with non-users, HR = 1.03, 95% CI = 0.84, 1.28
for intermittent users; HR = 1.11, 95% CI = 0.88, 1.39
for persistent users; multivariate model 5). Similar re-
sults were obtained when the analyses focused on per-
sistent BZD users in comparison to non persistent BZD
users or non BZD users.
We also examined the impact of past hypnotic intake
duration and compared participants who were not taking
sleep medication at baseline with those having previouslyreported taking sleep medications for less than 5 years, be-
tween 5 and 10 years, between 10 and 20 years, and for
more than 20 years. No significant association was ob-
served between duration of hypnotic intake and all-cause
mortality, the global P-value ranging from 0.18 (model 1)
to 0.76 (model 5) (data not shown).Discussion
This study examined associations between hypnotic in-
take and risk of excess mortality (all-causes and specific
causes) over a 12-year period in a large elderly cohort, tak-
ing into account a wide range of potential confounding fac-
tors. As in several previous studies we observed significant
associations between hypnotic use, notably BZDs, and mor-
tality; however, these associations became non-significant
after adjustment for all potential confounding factors, not-
ably psychiatric disorder. These findings persisted even
after taking into account up to 20 years duration of past
hypnotic intake or persistent versus intermittent use.
Previous studies have been inconsistent, with some
studies observing significant relationships between hyp-
notic prescriptions and mortality [16,20-25,37] and others
not [16-19]. Our findings suggest that these differences
are probably largely due to failure to take into account
confounding associations, notably common affective symp-
toms and sleep complaints, although other factors such as
study design, participant age, and class of hypnotics prob-
ably also influence study outcome.
Insomnia symptoms often lead to the use of hypnotics,
a condition frequently associated with EDS, anxiety, and
mood disorders. Depression and anxiety are also risk
factors for mortality [14,15]. Depressive symptomatology
and insomnia are both common in the elderly and in
France there are no official guidelines for management,
so antidepressants are often used to treat sleep disorder
and hypnotics to treat depression, especially where sleep
disturbance is one of the presenting symptoms [2]. EDS
Table 2 Baseline predictors of deaths from all causes during follow-up
Deaths-all causes
No N = 5,389 Yes N = 1,307
Variable n % n % Hazard ratio [95% CI]a Pa
High level of educationb No 4,337 80.48 1,044 79.88 1 0.06
Yes 1,052 19.52 263 20.12 0.87 [0.76;1.00]
Living alone Yes 1,782 33.07 433 33.13 1 0.84
No 3,607 66.93 874 66.87 1.01 [0.89;1.15]
Confinement No 5,181 96.14 1,158 88.60 1 0.0001
Yes 208 3.86 149 11.40 1.78 [1.49;2.13]
Alcohol intake (g/day) <12 1,062 19.71 242 18.52 1.23 [1.06;1.42] 0.01
12 to 36 3,900 72.37 911 69.70 1
>36 427 7.92 154 11.78 1.14 [0.96;1.36]
Caffeine intake (mg/day) ≤125 1,362 25.27 371 28.39 1 0.86
125 to 375 3,164 58.71 775 59.30 0.97 [0.85;1.09]
>375 863 16.01 161 12.32 0.97 [0.81;1.17]
Smoking status Never 3,368 62.50 634 48.51 1 <0.0001
Past 1,740 32.29 563 43.08 1.22 [1.07;1.40]
Current 281 5.21 110 8.42 1.73 [1.41;2.14]
History of cardiovascular diseasec No 4,079 75.69 768 58.76 1 0.0001
Yes 1,310 24.31 539 41.24 1.49 [1.33;1.67]
Respiratory disease No 5,121 95.03 1,188 90.90 1 0.0001
Yes 268 4.97 119 9.10 1.64 [1.36;1.98]
Thyroid disease No 4,890 90.74 1,219 93.27 1 0.19
Yes 499 9.26 88 6.73 1.16 [0.93;1.45]
Depressive symptomatology No 4,209 78.10 983 75.21 1 0.0005
Yes 1,180 21.90 324 24.79 1.26 [1.11;1.43]
Antidepressant use No 5,072 94.12 1,205 92.20 1 0.0002
Yes 317 5.88 102 7.80 1.47 [1.20;1.80]
Spielberger trait anxiety <43 3,509 65.11 894 68.40 1 0.13
≥43 1,880 34.89 413 31.60 1.10 [0.97;1.23]
Mini Mental State Examination Score ≥ 26 4,666 86.58 1,083 82.86 1 0.005
<26 723 13.42 224 17.14 1.23 [1.07;1.43]
Body mass index (kg/m2) Normal (<25) 2,611 48.45 613 46.90 1 0.0007
Overweight (25 to 29) 2,118 39.30 503 38.49 1.01 [0.90;1.14]
Obese (≥30) 660 12.25 191 14.61 1.36 [1.15;1.60]
Hypertension No 2,313 42.92 400 30.60 1 0.002
Yes 3,076 57.08 907 69.40 1.21 [1.07;1.36]
Diabetes mellitus No 4,965 92.13 1,126 86.15 1 0.0001
Yes 424 7.87 181 13.85 1.58 [1.35;1.85]
Hypercholesterolemia No 3,333 61.85 875 66.95 1 0.99
Yes 2,056 38.15 432 33.05 1.00 [0.89;1.12]
Snoring loudly (n = 5,972) Never/Rarely 3,114 64.93 770 65.48 1 0.90
Frequently/Often 1,682 35.07 406 34.52 1.01 [0.89;1.14]
Difficulties in initiating sleep Never/Rarely 3,506 65.06 895 68.48 1 0.20
Frequently/Often 1,883 34.94 412 31.52 0.92 [0.81;1.04]
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Table 2 Baseline predictors of deaths from all causes during follow-up (Continued)
Difficulties in maintaining sleep Never/Rarely 2,055 38.13 429 32.82 1 0.26
Frequently/Often 3,334 61.87 878 67.18 1.07 [0.95;1.20]
Early morning awakening Never/Rarely 3,434 63.72 871 66.64 1 0.12
Frequently/Often 1,955 36.28 436 33.36 0.91 [0.81;1.02]
Number of insomnia complaintsd 0 1,526 28.32 320 24.48 1 0.07
1 1,595 29.60 460 35.20 1.14 [0.99;1.31]
2 1,227 22.77 315 24.10 1.08 [0.92;1.26]
3 1,041 19.32 212 16.22 0.92 [0.77;1.11]
Excessive daytime sleepiness Never/Rarely 4,555 84.52 994 76.05 1 0.003
Frequently/Often 834 15.48 313 23.95 1.23 [1.07;1.40]
aAdjusted for center study, gender and age; buniversity level; chistory of cardiovascular disease (stroke or coronary heart disease; dnumber of insomnia complaints:
difficulties in initiating sleep + difficulties in maintaining sleep + early morning awakening.
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http://www.biomedcentral.com/1741-7015/11/212is also of multifactorial origin, and commonly associated
with depression [7], cognitive decline [38], physical ill-
ness (particularly CVD), and mortality in older adults
[5,6,13]. Thus, all these conditions may increase the risk
of mortality in elderly patients through pathways inde-
pendently of hypnotics. However, few previous studies
have controlled for psychological status [17,18,22,23]
and in studies where depressive symptoms have beenTable 3 Risks of death from all causes over 12-year according
All-cause death
No Yes Model 1a Model 2
N = 5,389 N = 1,307
Variable n % n % HR [95% CI] P HR [95% CI]
Hypnotic use
No 4,261 79.07 981 75.06 1 0.007 1
Yes 1,128 20.93 326 24.94 1.19 [1.05;1.36] 1.10 [0.96;1.25]
Number of hypnotics
0 4,261 79.07 981 75.06 1 0.003 1
1 970 18.00 272 20.81 1.14 [0.99;1.31] 1.06 [0.93;1.22]
≥2 158 2.93 54 4.13 1.53 [1.16;2.01] 1.32 [1.00;1.74]
BZD
No 4,557 84.56 1069 81.79 1 0.003 1
Yes 832 15.44 238 18.21 1.24 [1.08;1.44] 1.15 [1.00;1.33]
BZD-like compounds
No 5,135 95.29 1240 94.87 1 0.93 1
Yes 254 4.71 67 5.13 1.01 [0.79;1.29] 0.93 [0.72;1.19]
Miscellaneous medications
No 5,241 97.25 1251 95.72 1 0.15 1
Yes 148 2.75 56 4.28 1.22 [0.93;1.60] 1.15 [0.88;1.51]
aAdjusted for age, study center, and gender; badjusted for age, study center, gende
cardio and cerebrovascular disease, respiratory disease, Mini Mental State Examinat
all the covariates in model 2, plus excessive daytime sleepiness and number of inso
symptoms, antidepressant use and Spielberger trait anxiety score; eadjusted for all
Spielberger trait anxiety score. BZD, benzodiazepines; CI, confidence interval; HR, haconsidered, antidepressant use has not been necessarily
taken into account. This is important because anti-
depressant use may relieve depressive symptomatology,
but the underlying biological risk factors associated with
increased mortality may still be operating. No previous
studies have controlled for anxiety or simultaneously for
insomnia and EDS symptoms as potential independent
confounding factors. To our knowledge, our study is theto hypnotic use
b Model 3c Model 4d Model 5e
P HR [95% CI] P HR [95% CI] P HR [95% CI] P
0.16 1 0.12 1 0.50 1 0.43
1.12 [0.97;1.29] 1.05 [0.92;1.20] 1.06 [0.92;1.23]
0.13 1 0.13 1 0.44 1 0.47
1.09 [0.94;1.26] 1.02 [0.89;1.18] 1.04 [0.89;1.21]
1.33 [0.98;1.81] 1.20 [0.90;1.60] 1.21 [0.88;1.65]
0.05 1 0.05 1 0.22 1 0.21
1.17 [1.00;1.37] 1.10 [0.95;1.28] 1.11 [0.94;1.30]
0.56 1 0.76 1 0.40 1 0.55
0.96 [0.74;1.25] 0.90 [0.70;1.15] 0.92 [0.71;1.20]
0.30 1 0.32 1 0.49 1 0.49
1.16 [0.87;1.55] 1.10 [0.84;1.45] 1.11 [0.83;1.48]
r, level of education, confinement, alcohol intake, smoking status, history of
ion score, body mass index, hypertension, and diabetes mellitus; cadjusted for
mnia complaints; dadjusted for all the covariates in model 2, plus depressive
the covariates in model 3 plus depressive symptoms, antidepressants use and
zard ratios.
Table 4 Risks of cardiovascular disease and cancer as causes of death over 12 years according hypnotic use
Cardiovascular disease deaths Cancer deaths
No n = 6,311 Yes N = 385 Model 1a Model 2b No n = 6,174 Yes N = 522 Model 1a Model 2b
Variable n % n % HR [95% CI] P HR [95% CI] P n % n % HR [95% CI] P HR [95% CI] P
Hypnotic use
No 4,962 78.62 280 72.73 1 0.02 1 0.56 4,818 78.04 424 81.23 1 0.38 1 0.73
Yes 1,349 21.38 105 27.27 1.32 [1.04;1.66] 0.92 [0.71;1.20] 1,356 21.96 98 18.77 0.90 [0.72;1.13] 0.96 [0.74;1.23]
Number of hypnotics
0 4,962 78.62 280 72.73 1 0.03 1 0.78 4,818 78.04 424 81.23 1 0.67 1 0.94
1 1,154 18.29 88 22.86 1.26 [0.99;1.61] 0.94 [0.72;1.23] 1,157 18.74 85 16.28 0.91 [0.72;1.15] 0.96 [0.74;1.25]
≥2 195 3.09 17 4.42 1.69 [1.03;2.76] 0.83 [0.45;1.52] 199 3.22 13 2.49 0.89 [0.51;1.54] 0.93 [0.50;1.72]
BZD
No 5,321 84.31 305 79.22 1 0.004 1 0.60 5,170 83.74 456 87.36 1 0.27 1 0.42
Yes 990 15.69 80 20.78 1.45 [1.13;1.87] 1.08 [0.81;1.43] 1,004 16.26 66 12.64 0.86 [0.66;1.12] 0.89 [0.66;1.19]
BZD-like compounds
No 6,008 95.20 367 95.32 1 0.65 1 0.12 5,879 95.22 496 95.02 1 0.78 1 0.44
Yes 303 4.80 18 4.68 0.90 [0.56;1.44] 0.67 [0.40;1.11] 295 4.78 26 4.98 1.06 [0.71;1.57] 1.18 [0.77;1.82]
Miscellaneous medications
No 6,123 97.02 369 95.84 1 0.64 1 0.43 5,986 96.95 506 96.93 1 0.88 1 0.95
Yes 188 2.98 16 4.16 1.13 [0.68;1.87] 0.80 [0.45;1.41] 188 3.05 16 3.07 0.96 [0.58;1.59] 1.02 [0.59;1.74]
aAdjusted for age, study center, and gender; badjusted for all covariates in model 1 plus high level of education, confinement, alcohol intake, smoking status, history of cardio-cerebrovascular disease, respiratory
disease, Mini Mental State Examination score, body mass index, hypertension and diabetes mellitus, depressive symptoms, antidepressants use, Spielberger trait anxiety score, excessive daytime sleepiness, and
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confounding factors, especially the underlying diseases
associated with hypnotic use, such as anxiety and de-
pressive symptomatology and antidepressant use, as well
as EDS and insomnia complaints. Our finding that psy-
chiatric disorder could be a principal determinant driv-
ing the association between hypnotics and mortality risk
explains previous inconsistencies.
Chronic use of hypnotic drugs, particularly BZD, may
be associated with the risk of addiction and insomnia-
rebound after withdrawal, psychomotor impairment
and cognitive problems, OSAS, EDS, and car accidents
[12,39,40]. In our sample, only one participant died from a
car accident, and this person did not use hypnotics. We
did not find any interaction between individuals clinic-
ally at risk for OSAS, hypnotics intake, and mortality,
suggesting that if hypnotics trigger or aggravate OSAS
they do not impact on mortality risk. The use of BZD may
also favor falls and hip fractures and thus increase the risk
for disability and death especially in the elderly [41,42].
However some studies have suggested that nighttime sleep
problems may also be significant risk factors for falls in
the elderly, independently of hypnotic use [43-45]. In
our study, the associations between hypnotic use and all-
causes or CVD-related death became non-significant after
adjustment for health behavior and status variables, plus
EDS and insomnia complaints.
An increased incidence risk for cancer was also
reported in individuals using hypnotics in some studies
[21,22,24], even in infrequent hypnotic users [22]. Our
study did not report any association between hypnotic
use and cancer-related death. Again, differences in ad-
justment of underlying co-morbid conditions frequently
associated with the chronic use of hypnotics appear to
explain previous findings.
The present study has some limitations. Unfortunately,
data related to hypnotic dose were not available. Bias
could have been introduced by the low participation rate
at baseline and the non-random exclusion of participants
with missing data at baseline – these participants were
older, were more commonly hypnotics users, and more
often had psychiatric and other chronic disorders that
may limit the generalizability of our findings. Although
unlikely, the possibility of overadjusment can not be ex-
cluded: potential confounding variables should be inter-
mediate variables in the causal pathway between hypnotics
intake and mortality. Finally, the absence of significant
association between the use of hypnotics and mortal-
ity (all-causes, and CVD) after adjustments for covari-
ates should be interpreted with caution regarding the
small number of events per predictor variable.
Our prospective study based on a large community
sample has several strengths, including the duration of the
follow-up and adjustment for a wide range of possibleconfounding factors including sociodemographic and life-
style factors, chronic disorders, and sleep complaints as
well as depression and anxiety disorders that were found
as key confounding factors in this study. Prescriptions and
medications themselves were checked by the interviewer
and the causes of death were established by an independ-
ent committee. Finally, excluding participants who died
during the first two years of follow-up did not modify the
main results, suggesting a modest confounding effect of
severe undiagnosed conditions in relation to hypnotic use
and death.
Conclusions
Our findings suggest that the use of hypnotics is not inde-
pendently associated with an increased risk of mortality in
the elderly, and that previous findings may be largely at-
tributable to failure to take into account confounding vari-
ables, notably clinical co-morbidity, which is frequent at
higher ages, particularly psychiatric disorders. Use of hyp-
notics might be a marker underlying more complex health
issues.
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